Contact Congress about H.R. 2343: John W. Walsh Alpha-1 Home Infusion Act of 2025

Some adults with Alpha-1 disease could get treatment at home through Medicare Part B. Medicare would pay for the IV kit and up to two hours of nursing care per treatment, starting January 1, 2027.

Modern Action explains what the legislation does, helps you choose whether to support, oppose, or ask for changes, and drafts a message tied to the bill, your stance, and the elected officials who can act on it.

John W. Walsh Alpha-1 Home Infusion Act of 2025 is a House bill in committee. The latest recorded action: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Latest action on H.R. 2343: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Who this affects: This bill mainly affects adults in traditional Medicare who have severe inherited Alpha-1 Antitrypsin deficiency and emphysema. It could let them receive covered treatment at home instead of going to a clinic or other facility. It also affects home infusion suppliers and nurses, because it creates a direct Medicare payment path for this care. People in Medicare Advantage would not get this new Part B benefit through the bill.

Why this matters: This bill could make long-term Alpha-1 treatment easier for some Medicare patients by moving covered care into the home. That may reduce trips to a clinic or hospital for people who meet the rules. It also gives suppliers a clearer way to get paid for this specific service. The real effect would depend on the payment rates, supplier participation, and how many patients use the benefit.

Key provisions in H.R. 2343

• The bill defines covered Alpha-1 treatment as augmentation therapy given at home. A qualified home infusion therapy supplier must provide it.
• Adults qualify only if they have signs of emphysema caused by severe inherited Alpha-1 Antitrypsin deficiency. They must have Medicare Part A and Part B and cannot be in Medicare Advantage, also called Part C.
• The patient must be cared for by a doctor, nurse practitioner, or physician assistant.
• The bill uses Medicare’s current definition of a qualified home infusion therapy supplier. That rule decides who may provide the service and bill Medicare.
• The Secretary of Health and Human Services must create a Medicare Part B payment system. It would cover IV administration kits and nursing services tied to Alpha-1 augmentation therapy.

How Modern Action helps you take action on H.R. 2343

You do not have to start with a blank letter. Modern Action turns the bill, your position, and the relevant congressional context into a message you can edit and send. The goal is to make contacting Congress clear, specific, and useful without forcing you to parse bill text or figure out the right office on your own.

Questions people ask about H.R. 2343

What is H.R. 2343?

Some adults with Alpha-1 disease could get treatment at home through Medicare Part B. Medicare would pay for the IV kit and up to two hours of nursing care per treatment, starting January 1, 2027.

How do I support or oppose H.R. 2343?

Choose support, oppose, or ask for changes on Modern Action. The action flow drafts the message for you and keeps the wording tied to this bill.

Who should I contact about H.R. 2343?

Modern Action uses your location to route the action to the congressional offices relevant to the bill and your representation.

How does Modern Action help me act on H.R. 2343?

Modern Action gives you bill-specific context, lets you choose support, opposition, or changes, and drafts a message from your position and reasons.